Search

Your search keyword '"Wetzels, Jack"' showing total 1,501 results
Start Over Author "Wetzels, Jack"
1,501 results on '"Wetzels, Jack"'

1. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy

Author

Rovin, Brad H., Ronco, Pierre M., Wetzels, Jack F.M., Adler, Sharon G., Ayoub, Isabelle, Zaoui, Philippe, Han, Seung Hyeok, Dudani, Jaideep S., Gilbert, Houston N., Patel, Uptal D., Manser, Paul T., Jauch-Lembach, Julia, Faulhaber, Nicola, Boxhammer, Rainer, Härtle, Stefan, and Sprangers, Ben

Published
2024
Full Text
View/download PDF

2. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

Author

Inker, Lesley A., Collier, Willem, Greene, Tom, Miao, Shiyuan, Chaudhari, Juhi, Appel, Gerald B., Badve, Sunil V., Caravaca-Fontán, Fernando, Del Vecchio, Lucia, Floege, Jürgen, Goicoechea, Marian, Haaland, Benjamin, Herrington, William G., Imai, Enyu, Jafar, Tazeen H., Lewis, Julia B., Li, Philip K. T., Maes, Bart D., Neuen, Brendon L., Perrone, Ronald D., Remuzzi, Giuseppe, Schena, Francesco P., Wanner, Christoph, Wetzels, Jack F. M., Woodward, Mark, and Heerspink, Hiddo J. L.

Published
2023
Full Text
View/download PDF

5. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

Author

Trautmann, Agnes, Boyer, Olivia, Hodson, Elisabeth, Bagga, Arvind, Gipson, Debbie S., Samuel, Susan, and Wetzels, Jack

Subjects
Practice guidelines (Medicine) -- Methods, Nephrotic syndrome -- Diagnosis -- Care and treatment, Nephrologists -- Practice, Transitional care -- Services, Health
Abstract

Idiopathic nephrotic syndrome is the most frequent pediatric glomerular disease, affecting from 1.15 to 16.9 per 100,000 children per year globally. It is characterized by massive proteinuria, hypoalbuminemia, and/or concomitant edema. Approximately 85-90% of patients attain complete remission of proteinuria within 4-6 weeks of treatment with glucocorticoids, and therefore, have steroid-sensitive nephrotic syndrome (SSNS). Among those patients who are steroid sensitive, 70-80% will have at least one relapse during follow-up, and up to 50% of these patients will experience frequent relapses or become dependent on glucocorticoids to maintain remission. The dose and duration of steroid treatment to prolong time between relapses remains a subject of much debate, and patients continue to experience a high prevalence of steroid-related morbidity. Various steroid-sparing immunosuppressive drugs have been used in clinical practice; however, there is marked practice variation in the selection of these drugs and timing of their introduction during the course of the disease. Therefore, international evidence-based clinical practice recommendations (CPRs) are needed to guide clinical practice and reduce practice variation. The International Pediatric Nephrology Association (IPNA) convened a team of experts including pediatric nephrologists, an adult nephrologist, and a patient representative to develop comprehensive CPRs on the diagnosis and management of SSNS in children. After performing a systematic literature review on 12 clinically relevant PICO (Patient or Population covered, Intervention, Comparator, Outcome) questions, recommendations were formulated and formally graded at several virtual consensus meetings. New definitions for treatment outcomes to help guide change of therapy and recommendations for important research questions are given., Author(s): Agnes Trautmann [sup.1] , Olivia Boyer [sup.2] , Elisabeth Hodson [sup.3] , Arvind Bagga [sup.4] , Debbie S. Gipson [sup.5] , Susan Samuel [sup.6] , Jack Wetzels [sup.7] , [...]

Published
2023
Full Text
View/download PDF

6. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification

Author

Sethi, Sanjeev, Beck, Laurence H., Jr., Glassock, Richard J., Haas, Mark, De Vriese, An S., Caza, Tiffany N., Hoxha, Elion, Lambeau, Gérard, Tomas, Nicola M., Madden, Benjamin, Debiec, Hanna, D’Agati, Vivette D., Alexander, Mariam P., Amer, Hatem, Appel, Gerald B., Barbour, Sean J., Caravaca-Fontan, Fernando, Cattran, Daniel C., Casal Moura, Marta, D’Avila, Domingos O., Eick, Renato G., Garovic, Vesna D., Greene, Eddie L., Herrera Hernandez, Loren P., Jennette, J. Charles, Lieske, John C., Markowitz, Glen S., Nath, Karl A., Nasr, Samih H., Nast, Cynthia C., Pani, Antonello, Praga, Manuel, Remuzzi, Giuseppe, Rennke, Helmut G., Ruggenenti, Piero, Roccatello, Dario, Soler, Maria Jose, Specks, Ulrich, Stahl, Rolf A.K., Singh, Raman Deep, Theis, Jason D., Velosa, Jorge A., Wetzels, Jack F.M., Winearls, Christopher G., Yandian, Federico, Zand, Ladan, Ronco, Pierre, and Fervenza, Fernando C.

Published
2023
Full Text
View/download PDF

8. Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation

Author

van Zuijlen, A.D., Berger, Dr.SP., Bemelman, F.J., van der Heijden, J.W., van de Wetering, J., de Vries, A.P.J., Wetzels, J.F.M., van Wijk, J.A.E., Bouts, A.H.M., Dorresteijn, E.M., Gracchi, V., Horuz-Engels, F.A.P.T., Keijzer-Veen, M.G., van Rooij, R.W.G., van de Kar, N.C.A.J., van den Heuvel, L.P., Duineveld, Caroline, Bouwmeester, Romy N., Wijnsma, Kioa L., Berger, S.P., van den Heuvel, L.P.W.J., van de Kar, Nicole C.A.J., and Wetzels, Jack F.M.

Published
2023
Full Text
View/download PDF

11. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management

Author

Fakhouri, Fadi, Schwotzer, Nora, Cabiddu, Gianfranca, Barratt, Jonathan, Legardeur, Hélène, Garovic, Vesna, Orozco-Guillen, Alejandra, Wetzels, Jack, Daugas, Eric, Moroni, Gabriella, Noris, Marina, Audard, Vincent, Praga, Manuel, Llurba, Elisa, Wuerzner, Grégoire, Attini, Rossella, Desseauve, David, Zakharova, Elena, Luders, Claudio, Wiles, Kate, Leone, Filomena, Jesudason, Shilpanjali, Costedoat-Chalumeau, Nathalie, Kattah, Andrea, Soto-Abraham, Virgilia, Karras, Alexandre, Prakash, Jai, Lightstone, Liz, Ronco, Pierre, Ponticelli, Claudio, Appel, Gerald, Remuzzi, Giuseppe, Tsatsaris, Vassilis, and Piccoli, Giorgina Barbara

Published
2023
Full Text
View/download PDF

13. Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study

Author

Bouwmeester, Romy N., Duineveld, Caroline, Wijnsma, Kioa L., Bemelman, Frederike J., van der Heijden, Joost W., van Wijk, Joanna A.E., Bouts, Antonia H.M., van de Wetering, Jacqueline, Dorresteijn, Eiske, Berger, Stefan P., Gracchi, Valentina, van Zuilen, Arjan D., Keijzer-Veen, Mandy G., de Vries, Aiko P.J., van Rooij, Roos W.G., Engels, Flore A.P.T., Altena, Wim, de Wildt, Renée, van Kempen, Evy, Adang, Eddy M., ter Avest, Mendy, ter Heine, Rob, Volokhina, Elena B., van den Heuvel, Lambertus P.W.J., Wetzels, Jack F.M., and van de Kar, Nicole C.A.J.

Published
2023
Full Text
View/download PDF

18. Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442–1451

Author

Astor, Brad, Appel, Lawrence J, Levin, Adeera, Tang, Mila, Djurdjev, Ognjenka, Navaneethan, Sankar D, Jolly, Stacey E, Schold, Jesse D, Nally, Joseph V, Wheeler, David C, Emberson, Jonathan, Townend, John, Landray, Martin, Feldman, Harold I, Hsu, Chi-yuan, Lash, James P, Kalra, Philip A, Ritchie, James P, Maharajan, Raman, Middleton, Rachel J, O’Donoghue, Donal J, Eckardt, Kai-Uwe, Schneider, Markus P, Köttgen, Anna, Kronenberg, Florian, Bärthlein, Barbara, Chang, Alex R, Green, Jamie A, Kirchner, H Lester, Ho, Kevin, Marks, Angharad, Black, Corri, Prescott, Gordon J, Fluck, Nick, Nakayama, Masaaki, Miyazaki, Mariko, Yamamoto, Tae, Yamada, Wang, Angela Yee-Moon, Cheung, Sharon, Wong, Sharon, Chu, Jessie, Wu, Henry, Garg, Amit X, McArthur, Eric, Nash, Danielle M, Shalev, Varda, Chodick, Gabriel, Blankestijn, Peter J, Wetzels, Jack FM, van Zuilen, Arjan D, van den Brand, Jan A, Levey, Andrew S, Inker, Lesley A, Sarnak, Mark J, Tighiouart, Hocine, Zhang, Haitao, Stengel, Benedicte, Metzger, Marie, Flamant, Martin, Houillier, Pascal, Haymann, Jean-Philippe, Rios, Pablo G, Mazzuchi, Nelson, Gadola, Liliana, Lamadrid, Verónica, Sola, Laura, Collins, John F, Elley, C Raina, Kenealy, Timothy, Moranne, Olivier, Couchoud, Cecile, Vigneau, Cecile, Brunskill, Nigel J, Major, Rupert W, Shepherd, David, Medcalf, James F, Kovesdy, Csaba P, Kalantar-Zadeh, Kamyar, Molnar, Miklos Z, Sumida, Keiichi, Potukuchi, Praveen K, Heerspink, Hiddo JL, de Zeeuw, Dick, Brenner, Barry, Carrero, Juan Jesus, Gasparini, Alessandro, Qureshi, Abdul Rashid, Elinder, Carl-Gustaf, Visseren, Frank LJ, van der Graaf, Yolanda, Evans, Marie, Stendahl, Maria, Schön, Staffan, Segelmark, Mårten, Prütz, Karl-Göran, Naimark, David M, Tangri, Navdeep, and Mark, Patrick B

Subjects
Renal and urogenital, Chronic Kidney Disease Prognosis Consortium, Clinical Sciences, Urology & Nephrology
Abstract

The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr.; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Rachel J. Middleton, Donal J. O'Donoghue; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Ontario Institute for Clinical Evaluative Sciences, Provincial Kidney, Dialysis and Transplantation program (ICES KDT): Amit X. Garg, Eric McArthur, Danielle M. Nash; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study (NephroTest): Benedicte Stengel, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Verónica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agées (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Alessandro Gasparini, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Köttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).

Published
2018

19. Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637

Author

Astor, Brad, Appel, Lawrence J, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Navaneethan, Sankar D, Jolly, Stacey E, Schold, Jesse D, Nally, Joseph V, Wheeler, David C, Emberson, Jonathan, Townend, John, Landray, Martin, Feldman, Harold I, Hsu, Chi-yuan, Lash, James P, Kalra, Philip A, Ritchie, James P, Maharajan, Raman, Alderson, Helen, Lane, Beverly, Eckardt, Kai-Uwe, Schneider, Markus P, Köttgen, Anna, Kronenberg, Florian, Bärthlein, Barbara, Chang, Alex R, Green, Jamie A, Kirchner, H Lester, Ho, Kevin, Marks, Angharad, Black, Corri, Prescott, Gordon J, Fluck, Nick, Nakayama, Masaaki, Miyazaki, Mariko, Yamamoto, Tae, Yamada, Wang, Angela Yee-Moon, Cheung, Sharon, Wong, Sharon, Chu, Jessie, Wu, Henry, Shalev, Varda, Chodick, Gabriel, Blankestijn, Peter J, Wetzels, Jack FM, van Zuilen, Arjan D, van den Brand, Jan A, Levey, Andrew S, Inker, Lesley A, Sarnak, Mark J, Tighiouart, Hocine, Zhang, Haitao, Stengel, Benedicte, Rios, Pablo G, Mazzuchi, Nelson, Gadola, Liliana, Lamadrid, Verónica, Sola, Laura, Collins, John F, Elley, C Raina, Kenealy, Timothy, Moranne, Olivier, Couchoud, Cecile, Vigneau, Cecile, Brunskill, Nigel J, Major, Rupert W, Shepherd, David, Medcalf, James F, Kovesdy, Csaba P, Kalantar-Zadeh, Kamyar, Molnar, Miklos Z, Sumida, Keiichi, Potukuchi, Praveen K, Heerspink, Hiddo JL, de Zeeuw, Dick, Brenner, Barry, Carrero, Juan Jesus, Barany, Peter, Qureshi, Abdul Rashid, Elinder, Carl-Gustaf, Visseren, Frank LJ, van der Graaf, Yolanda, Evans, Marie, Stendahl, Maria, Schön, Staffan, Segelmark, Mårten, Prütz, Karl-Göran, Naimark, David M, Tangri, Navdeep, Mark, Patrick B, Traynor, Jamie P, Geddes, Colin C, Thomson, Peter C, and Coresh, Josef

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Renal and urogenital, Good Health and Well Being, Chronic Kidney Disease Prognosis Consortium, Biomedical and clinical sciences, Health sciences
Abstract

[This corrects the article DOI: 10.1016/j.ekir.2018.01.002.].

Published
2018

20. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.

Author

Kovesdy, Csaba P, Matsushita, Kunihiro, Sang, Yingying, Brunskill, Nigel J, Carrero, Juan J, Chodick, Gabriel, Hasegawa, Takeshi, Heerspink, Hiddo L, Hirayama, Atsushi, Landman, Gijs WD, Levin, Adeera, Nitsch, Dorothea, Wheeler, David C, Coresh, Josef, Hallan, Stein I, Shalev, Varda, Grams, Morgan E, Astor, Brad, Appel, Larry, Greene, Tom, Chen, Teresa, Chalmers, John, Woodward, Mark, Arima, Hisatomi, Perkovic, Vlado, Djurdjev, Ognjenka, Zhang, Luxia, Liu, Lisheng, Zhao, Minghui, Wang, Fang, Wang, Jinwei, Tang, Mila, Iso, Hiroyasu, Yamagishi, Kazumasa, Umesawa, Mitsumasa, Muraki, Isao, Fukagawa, Masafumi, Maruyama, Shoichi, Hamano, Takayuki, Fujii, Naohiko, Wheeler, David, Emberson, John, Townend, John, Landray, Martin, Green, Jamie, Kirchner, H Lester, Chang, Alex R, Cirillo, Massimo, Jee, Sun Ha, Kimm, Heejin, Mok, Yejin, Wetzels, Jack FM, Blankestijn, Peter J, van Zuilen, Arjan D, Bots, M, Sarnak, Mark, Inker, Lesley, Roderick, Paul, Fletcher, Astrid, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen B, Nadukuru, Rajiv, Brunskill, Nigel, Major, Rupert, Shepherd, David, Medcalf, James, Gansevoort, Ron T, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, Jassal, Simerjot K, Bergstrom, Jaclyn, Ix, Joachim H, Barrett-Connor, Elizabeth, Kovesdy, Csaba, Kalantar-Zadeh, Kamyar, de Zeeuw, Dick, Brenner, Barry, Gasparini, Alessandro, Elinder, Carl-Gustaf, Barany, Peter, Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Wen, Chi-Pang, and Tsao, Chwen-Keng

Subjects
Kidney Disease, Prevention, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Renal and urogenital, Cardiovascular, Good Health and Well Being, Adult, Aged, Albuminuria, Cardiovascular Diseases, Cause of Death, Comorbidity, Glomerular Filtration Rate, Humans, Hyperkalemia, Hypokalemia, Kidney Failure, Chronic, Middle Aged, Prognosis, Renal Insufficiency, Chronic, Risk Factors, Potassium, Estimated glomerular filtration rate, End-stage renal disease, Mortality, CKD Prognosis Consortium, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsBoth hypo- and hyperkalaemia can have immediate deleterious physiological effects, and less is known about long-term risks. The objective was to determine the risks of all-cause mortality, cardiovascular mortality, and end-stage renal disease associated with potassium levels across the range of kidney function and evaluate for consistency across cohorts in a global consortium.Methods and resultsWe performed an individual-level data meta-analysis of 27 international cohorts [10 general population, 7 high cardiovascular risk, and 10 chronic kidney disease (CKD)] in the CKD Prognosis Consortium. We used Cox regression followed by random-effects meta-analysis to assess the relationship between baseline potassium and adverse outcomes, adjusted for demographic and clinical characteristics, overall and across strata of estimated glomerular filtration rate (eGFR) and albuminuria. We included 1 217 986 participants followed up for a mean of 6.9 years. The average age was 55 ± 16 years, average eGFR was 83 ± 23 mL/min/1.73 m2, and 17% had moderate- to-severe increased albuminuria levels. The mean baseline potassium was 4.2 ± 0.4 mmol/L. The risk of serum potassium of >5.5 mmol/L was related to lower eGFR and higher albuminuria. The risk relationship between potassium levels and adverse outcomes was U-shaped, with the lowest risk at serum potassium of 4-4.5 mmol/L. Compared with a reference of 4.2 mmol/L, the adjusted hazard ratio for all-cause mortality was 1.22 [95% confidence interval (CI) 1.15-1.29] at 5.5 mmol/L and 1.49 (95% CI 1.26-1.76) at 3.0 mmol/L. Risks were similar by eGFR, albuminuria, renin-angiotensin-aldosterone system inhibitor use, and across cohorts.ConclusionsOutpatient potassium levels both above and below the normal range are consistently associated with adverse outcomes, with similar risk relationships across eGFR and albuminuria.

Published
2018

25. Functional tests to guide management in an adult with loss of function of type-1 angiotensin II receptor

Author

Viering, Daan H. H. M., Bech, Anneke P., de Baaij, Jeroen H. F., Steenbergen, Eric J., Danser, A. H. Jan, Wetzels, Jack F. M., and Bindels, René J. M.

Subjects
Angiotensin II receptor blockers, Renin-angiotensin system -- Methods, Fludrocortisone -- Health aspects, Kidney diseases -- Drug therapy, Health
Abstract

Background Genetic loss of function of AGT (angiotensinogen), REN (renin), ACE (angiotensin-converting enzyme), or AGTR1 (type-1 angiotensin II receptor) leads to renal tubular dysgenesis (RTD). This syndrome is almost invariably lethal. Most surviving patients reach stage 5 chronic kidney disease at a young age. Methods Here, we report a 28-year-old male with a homozygous truncating mutation in AGTR1 (p.Arg216*), who survived the perinatal period with a mildly impaired kidney function. In contrast to classic RTD, kidney biopsy showed proximal tubules that were mostly normal. During the subsequent three decades, we observed evidence of both tubular dysfunction (hyperkalemia, metabolic acidosis, salt-wasting and a urinary concentrating defect) and glomerular dysfunction (reduced glomerular filtration rate, currently ~30 mL/min/1.73 m.sup.2, accompanied by proteinuria). To investigate the recurrent and severe hyperkalemia, we performed a patient-tailored functional test and showed that high doses of fludrocortisone induced renal potassium excretion by 155%. Furthermore, fludrocortisone lowered renal sodium excretion by 39%, which would have a mitigating effect on salt-wasting. In addition, urinary pH decreased in response to fludrocortisone. Opposite effects on urinary potassium and pH occurred with administration of amiloride, further supporting the notion that a collecting duct is present and able to react to fludrocortisone. Conclusions This report provides living proof that even truncating loss-of-function mutations in AGTR1 are compatible with life and relatively good GFR and provides evidence for the prescription of fludrocortisone to treat hyperkalemia and salt-wasting in such patients., Author(s): Daan H. H. M. Viering [sup.1] , Anneke P. Bech [sup.2] , Jeroen H. F. de Baaij [sup.1] , Eric J. Steenbergen [sup.3] , A. H. Jan Danser [sup.4] [...]

Published
2021
Full Text
View/download PDF

26. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Author

Rovin, Brad H., Adler, Sharon G., Barratt, Jonathan, Bridoux, Frank, Burdge, Kelly A., Chan, Tak Mao, Cook, H. Terence, Fervenza, Fernando C., Gibson, Keisha L., Glassock, Richard J., Jayne, David R.W., Jha, Vivekanand, Liew, Adrian, Liu, Zhi-Hong, Mejía-Vilet, Juan Manuel, Nester, Carla M., Radhakrishnan, Jai, Rave, Elizabeth M., Reich, Heather N., Ronco, Pierre, Sanders, Jan-Stephan F., Sethi, Sanjeev, Suzuki, Yusuke, Tang, Sydney C.W., Tesar, Vladimir, Vivarelli, Marina, Wetzels, Jack F.M., and Floege, Jürgen

Published
2021
Full Text
View/download PDF

27. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases

Author

Rovin, Brad H., Adler, Sharon G., Barratt, Jonathan, Bridoux, Frank, Burdge, Kelly A., Chan, Tak Mao, Cook, H. Terence, Fervenza, Fernando C., Gibson, Keisha L., Glassock, Richard J., Jayne, David R.W., Jha, Vivekanand, Liew, Adrian, Liu, Zhi-Hong, Mejía-Vilet, Juan M., Nester, Carla M., Radhakrishnan, Jai, Rave, Elizabeth M., Reich, Heather N., Ronco, Pierre, Sanders, Jan-Stephan F., Sethi, Sanjeev, Suzuki, Yusuke, Tang, Sydney C.W., Tesar, Vladimír, Vivarelli, Marina, Wetzels, Jack F.M., Lytvyn, Lyubov, Craig, Jonathan C., Tunnicliffe, David J., Howell, Martin, Tonelli, Marcello A., Cheung, Michael, Earley, Amy, and Floege, Jürgen

Published
2021
Full Text
View/download PDF

30. Rituximab in Membranous Nephropathy

Author

Gauckler, Philipp, Shin, Jae Il, Alberici, Federico, Audard, Vincent, Bruchfeld, Annette, Busch, Martin, Cheung, Chee Kay, Crnogorac, Matija, Delbarba, Elisa, Eller, Kathrin, Faguer, Stanislas, Galesic, Kresimir, Griffin, Siân, van den Hoogen, Martijn W.F., Hrušková, Zdenka, Jeyabalan, Anushya, Karras, Alexandre, King, Catherine, Kohli, Harbir Singh, Mayer, Gert, Maas, Rutger, Muto, Masahiro, Moiseev, Sergey, Odler, Balazs, Pepper, Ruth J., Quintana, Luis F., Radhakrishnan, Jai, Ramachandran, Raja, Salama, Alan D., Schönermarck, Ulf, Segelmark, Mårten, Smith, Lee, Tesař, Vladimír, Wetzels, Jack, Willcocks, Lisa, Windpessl, Martin, Zand, Ladan, Zonozi, Reza, and Kronbichler, Andreas

Published
2021
Full Text
View/download PDF

31. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

Author

Praga, Manuel, Sevillano, Angel, Caravaca-Fontan, Fernando, Trujillo, Hernando, Gutiérrez, Eduardo, Juarez, Gema Fernandez, Shabaka, Amir, Rojas-Rivera, Jorge, Egido, Jesus, Ortiz, Alberto, Goicoechea, Marian, Verdalles, Úrsula, Segarra, Alfons, Agraz, Irene, Martín-Reyes, Guillermo, Perea, Lara, Valera, Ildefonso, Martín, Mónica, Cabello, Virginia, Pérez Valdivia, Miguel Angel, Quintana, Luis F., Blasco, Miquel, Cao, Mercedes, Muñiz, Andrés López, Avila, Ana, Malek, Tamara, Espinosa, Mario, Rabasco, Cristina, Diaz, Montserrat, DaSilva, Iara, Bonet, Jordi, Navarro, Maruja, Gómez-Martino, Juan Ramón, Rivas, Begoña, Rodríguez-Moreno, Antolina, Galeano, Cristina, Romera, Ana, Huerta, Ana, Rodríguez-Paternina, Ezequiel, Vigil, Ana, Alcázar, Roberto, Paraíso, Vicente, Barrio, Vicente, Wetzels, Jack, Logt, Anne-Els van de, Hofstra, Julia, Fernández-Juárez, Gema, Justino, Joana, Caravaca-Fontán, Fernando, Ávila, Ana, Varela, Alfonso, Díez, Montserrat, Diezhandino, Marian Goicoechea, Bonet, Jose, Plaisier, Emmanuelle, Segarra, Alfonso, Lambeau, Gérard, and Ronco, Pierre

Published
2021
Full Text
View/download PDF

32. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients

Author

Berchtold, Lena, Letouzé, Eric, Alexander, Mariam Priya, Canaud, Guillaume, Logt, Anne-Els van de, Hamilton, Patrick, Mousson, Christiane, Vuiblet, Vincent, Moyer, Ann M., Guibert, Sylvain, Mrázová, Petra, Levi, Charlène, Dubois, Valérie, Cruzado, Josep Maria, Torres, Armando, Gandhi, Manish J., Yousfi, Nadhir, Tesar, Vladimir, Viklický, Ondřej, Hourmant, Maryvonne, Moulin, Bruno, Rieu, Philippe, Choukroun, Gabriel, Legendre, Christophe, Wetzels, Jack, Brenchley, Paul, Ballarín Castan, José Aurelio, Debiec, Hanna, and Ronco, Pierre

Published
2021
Full Text
View/download PDF

33. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data

Author

Matsushita, Kunihiro, Ballew, Shoshana H, Coresh, Josef, Arima, Hisatomi, Ärnlöv, Johan, Cirillo, Massimo, Ebert, Natalie, Hiramoto, Jade S, Kimm, Heejin, Shlipak, Michael G, Visseren, Frank LJ, Gansevoort, Ron T, Kovesdy, Csaba P, Shalev, Varda, Woodward, Mark, Kronenberg, Florian, Chalmers, John, Perkovic, Vlado, Grams, Morgan E, Sang, Yingying, Schaeffner, Elke, Martus, Peter, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Heine, Gunnar, Seiler, Sarah, Zawada, Adam, Emrich, Insa, Sarnak, Mark, Katz, Ronit, Brenner, Hermann, Schöttker, Ben, Rothenbacher, Dietrich, Saum, Kai-Uwe, Köttgen, Anna, Schneider, Markus, Eckardt, Kai-Uwe, Green, Jamie, Kirchner, H Lester, Chang, Alex R, Black, Corri, Marks, Angharad, Prescott, Gordon, Clark, Laura, Fluck, Nick, Jee, Sun Ha, Mok, Yejin, Chodick, Gabriel, Wetzels, Jack FM, Blankestijn, Peter J, van Zuilen, Arjan D, Bots, M, Peralta, Carmen, Hiromoto, Jade, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen B, Nadukuru, Rajiv, Kenealy, Timothy, Elley, C Raina, Collins, John F, Drury, Paul L, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, Jassal, Simerjot K, Bergstrom, Jaclyn, Ix, Joachim H, Barrett-Connor, Elizabeth, Kalantar-Zadeh, Kamyar, Carrero, Juan J, Gasparini, Alessandro, Qureshi, Abdul Rashid, Barany, Peter, Algra, Ale, van der Graaf, Yolanda, Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Lannfelt, Lars, Larsson, Anders, Hallan, Stein, Levey, Andrew S, Chen, Jingsha, and Kwak, Lucia

Subjects
Clinical Research, Kidney Disease, Prevention, Renal and urogenital, Good Health and Well Being, Adult, Aged, Albuminuria, Creatinine, Databases, Factual, Female, Glomerular Filtration Rate, Humans, Incidence, Male, Middle Aged, Peripheral Arterial Disease, Renal Insufficiency, Chronic, Risk Factors, Chronic Kidney Disease Prognosis Consortium, Medical Biochemistry and Metabolomics, Clinical Sciences, Public Health and Health Services
Abstract

BackgroundSome evidence suggests that chronic kidney disease is a risk factor for lower-extremity peripheral artery disease. We aimed to quantify the independent and joint associations of two measures of chronic kidney disease (estimated glomerular filtration rate [eGFR] and albuminuria) with the incidence of peripheral artery disease.MethodsIn this collaborative meta-analysis of international cohorts included in the Chronic Kidney Disease Prognosis Consortium (baseline measurements obtained between 1972 and 2014) with baseline measurements of eGFR and albuminuria, at least 1000 participants (this criterion not applied to cohorts exclusively enrolling patients with chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult participants without peripheral artery disease at baseline at the individual patient level with Cox proportional hazards models to quantify associations of creatinine-based eGFR, urine albumin-to-creatinine ratio (ACR), and dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, leg revascularisation, and leg amputation). We assessed discrimination improvement through c-statistics.FindingsWe analysed 817 084 individuals without a history of peripheral artery disease at baseline from 21 cohorts. 18 261 cases of peripheral artery disease were recorded during follow-up across cohorts (median follow-up was 7·4 years [IQR 5·7-8·9], range 2·0-15·8 years across cohorts). Both chronic kidney disease measures were independently associated with the incidence of peripheral artery disease. Compared with an eGFR of 95 mL/min per 1·73 m2, adjusted hazard ratios (HRs) for incident study-specific peripheral artery disease was 1·22 (95% CI 1·14-1·30) at an eGFR of 45 mL/min per 1·73 m2 and 2·06 (1·70-2·48) at an eGFR of 15 mL/min per 1·73 m2. Compared with an ACR of 5 mg/g, the adjusted HR for incident study-specific peripheral artery disease was 1·50 (1·41-1·59) at an ACR of 30 mg/g and 2·28 (2·12-2·44) at an ACR of 300 mg/g. The adjusted HR at an ACR of 300 mg/g versus 5 mg/g was 3·68 (95% CI 3·00-4·52) for leg amputation. eGFR and albuminuria contributed multiplicatively (eg, adjusted HR 5·76 [4·90-6·77] for incident peripheral artery disease and 10·61 [5·70-19·77] for amputation in eGFR

Published
2017

34. Trigenic COL4A3/COL4A4/COL4A5Pathogenic Variants in Alport Syndrome: A Case Report

Author

Rao, Dipti, Maas, Rutger, Cornelissen, Marlies, Wetzels, Jack, and van Geel, Michel

Abstract

Alport syndrome (AS) is a hereditary kidney disorder of type IV collagen caused by pathogenic variants in the COL4A3, COL4A4, and COL4A5genes. Previously several cases of digenic AS, caused by two pathogenic variants in two of the three COL4Agenes, have been reported. Patients with digenic AS may present with a more severe phenotype compared to patients with single variants, depending on the percentage affected type IV trimeric collagen chain. We report a newly discovered case of trigenic AS. A 52-year-old female presented with hematuria at the age of 24 years and developed hypertension by the age of 30. Over the years, she developed chronic kidney disease; the most recent eGFR was 44 mL/min/1.73 m2. She has symmetric high-tone sensorineural hearing loss. Full genetic analysis revealed a heterozygous pathogenic variant c.2691del in COL4A3,a heterozygous pathogenic variant c.1663dup in COL4A4,and a complete heterozygous deletion of COL4A5. We describe the first patient with AS caused by pathogenic variants in all three COL4Agenes, designated trigenic AS. This case report emphasizes the importance of examining all three COL4Agenes, even in patients with a mild Alport phenotype, for optimal follow-up of the patient and adequate genetic counseling of family members.

Published
2024
Full Text
View/download PDF

39. Standardized reporting of monoclonal immunoglobulin–associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group

Author

Sethi, Sanjeev, Nast, Cynthia C., D’Agati, Vivette D., Fervenza, Fernando C., Glassock, Richard J., Stokes, Michael B., De Vriese, An S., Appel, Gerald B., Chang, Anthony, Cosio, Fernando, Herrera Hernandez, Loren, Markowitz, Glen S., Kumar, Shaji K., Alexander, Mariam P., Amer, Hatem, Murray, David, Nasr, Samih H., Leung, Nelson, Pani, Antonello, Picken, Maria M., Ravindran, Aishwarya, Roccatello, Dario, Ronco, Pierre, Royal, Virginie, Smith, Kelly D., Wechalekar, Ashutosh D., Wetzels, Jack, Zand, Ladan, Zhang, Pingchuan, and Haas, Mark

Published
2020
Full Text
View/download PDF

40. C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy

Author

Zhang, Qi, primary, Bin, Sofia, additional, Budge, Kelly L., additional, Petrosyan, Astgik, additional, Villani, Valentina, additional, Aguiari, Paola, additional, Vink, Coralien H., additional, Wetzels, Jack, additional, Soloyan, Hasmik, additional, La Manna, Gaetano, additional, Podestà, Manuel Alfredo, additional, Molinari, Paolo, additional, Sedrakyan, Sargis, additional, Lemley, Kevin V., additional, De Filippo, Roger E., additional, Perin, Laura, additional, Cravedi, Paolo, additional, and Da Sacco, Stefano, additional

Published
2024
Full Text
View/download PDF

41. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney

Author

Verbinnen, Margo, primary, Sprangers, Ben, additional, Abrahams, Alferso C, additional, Koshy, Priyanka, additional, Van Kruijsdijk, Rob C M, additional, Philipse, Ester, additional, Michalak, Magdalena, additional, Delforge, Michel, additional, Vos, Josephine M I, additional, Wetzels, Jack, additional, Dendooven, Amélie, additional, and Van Craenenbroeck, Amaryllis H, additional

Published
2024
Full Text
View/download PDF

42. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification

Author

Sethi, Sanjeev, primary, Beck, Laurence H., additional, Glassock, Richard J., additional, Haas, Mark, additional, De Vriese, An S., additional, Caza, Tiffany N., additional, Hoxha, Elion, additional, Lambeau, Gérard, additional, Tomas, Nicola M., additional, Madden, Benjamin, additional, Debiec, Hanna, additional, D’Agati, Vivette D., additional, Alexander, Mariam P., additional, Amer, Hatem, additional, Appel, Gerald B., additional, Barbour, Sean J., additional, Caravaca-Fontan, Fernando, additional, Cattran, Daniel C., additional, Casal Moura, Marta, additional, D’Avila, Domingos O., additional, Eick, Renato G., additional, Garovic, Vesna D., additional, Greene, Eddie L., additional, Herrera Hernandez, Loren P., additional, Jennette, J. Charles, additional, Lieske, John C., additional, Markowitz, Glen S., additional, Nath, Karl A., additional, Nasr, Samih H., additional, Nast, Cynthia C., additional, Pani, Antonello, additional, Praga, Manuel, additional, Remuzzi, Giuseppe, additional, Rennke, Helmut G., additional, Ruggenenti, Piero, additional, Roccatello, Dario, additional, Soler, Maria Jose, additional, Specks, Ulrich, additional, Stahl, Rolf A.K., additional, Singh, Raman Deep, additional, Theis, Jason D., additional, Velosa, Jorge A., additional, Wetzels, Jack F.M., additional, Winearls, Christopher G., additional, Yandian, Federico, additional, Zand, Ladan, additional, Ronco, Pierre, additional, and Fervenza, Fernando C., additional

Published
2023
Full Text
View/download PDF

44. The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results

Author

Bassanese, Giulia, Wlodkowski, Tanja, Servais, Aude, Heidet, Laurence, Roccatello, Dario, Emma, Francesco, Levtchenko, Elena, Ariceta, Gema, Bacchetta, Justine, Capasso, Giovambattista, Jankauskiene, Augustina, Miglinas, Marius, Ferraro, Pietro Manuel, Montini, Giovanni, Oh, Jun, Decramer, Stephane, Levart, Tanja Kersnik, Wetzels, Jack, Cornelissen, Elisabeth, Devuyst, Olivier, Zurowska, Aleksandra, Pape, Lars, Buescher, Anja, Haffner, Dieter, Marcun Varda, Natasa, Ghiggeri, Gian Marco, Remuzzi, Giuseppe, Konrad, Martin, Longo, Germana, Bockenhauer, Detlef, Awan, Atif, Andersone, Ilze, Groothoff, Jaap W., and Schaefer, Franz

Published
2021
Full Text
View/download PDF

45. Membranous nephropathy

Author

Ronco, Pierre, Beck, Laurence, Debiec, Hanna, Fervenza, Fernando C., Hou, Fan Fan, Jha, Vivekanand, Sethi, Sanjeev, Tong, Allison, Vivarelli, Marina, and Wetzels, Jack

Published
2021
Full Text
View/download PDF

46. Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?

Author

Duineveld, Caroline, Steenbergen, Eric J., Bomback, Andrew S., van de Kar, Nicole C. A. J., and Wetzels, Jack F. M.

Subjects
Glomerulonephritis -- Diagnosis -- Care and treatment -- Demographic aspects -- Development and progression -- Patient outcomes, Nephrotic syndrome -- Diagnosis -- Development and progression -- Care and treatment -- Patient outcomes, Immunosuppressive agents -- Patient outcomes, Health
Abstract

Background The C3 glomerulopathies (C3G) are recently defined glomerular diseases, attributed to abnormal complement regulation. Dense deposit disease (DDD) is part of the spectrum of C3G, characterized by electron-dense deposits in the lamina densa of the glomerular basement membrane. Patients with DDD present with hematuria, variable degrees of proteinuria, and kidney dysfunction. Kidney biopsies typically disclose proliferative and inflammatory patterns of injury. Treatment with glucocorticoids and mycophenolate mofetil has been shown to achieve remission of proteinuria in a significant proportion of C3G patients. Case-diagnosis/treatment We report two patients with persistent nephrotic syndrome while on immunosuppressive therapy. Repeat kidney biopsies disclosed massive C3 deposits with foot process effacement in the absence of proliferative or inflammatory lesions on light microscopy. Conclusion These cases, coupled with data from animal models of disease and the variable response to eculizumab in C3G patients, illustrate that two different pathways might be involved in the development of kidney injury in C3G: a C5-independent pathway leading to glomerular capillary wall injury and the development of proteinuria versus a C5-dependent pathway that causes proliferative glomerulonephritis and kidney dysfunction., Author(s): Caroline Duineveld [sup.1] , Eric J. Steenbergen [sup.2] , Andrew S. Bomback [sup.3] , Nicole C. A. J. van de Kar [sup.4] , Jack F. M. Wetzels [sup.1] Author [...]

Published
2020
Full Text
View/download PDF

48. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease

Author

van Aerts, Rene M.M., Kievit, Wietske, D’Agnolo, Hedwig M.A., Blijdorp, Charles J., Casteleijn, Niek F., Dekker, Shosha E.I., de Fijter, Johan W., van Gastel, Maatje, Gevers, Tom J., van de Laarschot, Liyanne F.M., Lantinga, Marten A., Losekoot, Monique, Meijer, Esther, Messchendorp, A. Lianne, Neijenhuis, Myrte K., Pena, Michelle J., Peters, Dorien J.M., Salih, Mahdi, Soonawala, Darius, Spithoven, Edwin M., Visser, Folkert W., Wetzels, Jack F., Zietse, Robert, Gansevoort, Ron T., and Drenth, Joost P.H.

Published
2019
Full Text
View/download PDF

49. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Author

Appel, Lawrence J, Greene, Tom, Chen, Teresa K, Chalmers, John, Arima, Hisatomi, Perkovic, Vlado, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Nally, Joseph, Navaneethan, Sankar D, Schold, Jesse D, Weldegiorgis, Misghina, Herrington, William G, Smith, Margaret, Hsu, C Yenchih, Hwang, Shih-Jen, Chang, Alex R, Kirchner, H. Lester, Green, Jamie A, Ho, Kevin, Marks, Angharad, Prescott, Gordon, Clark, Laura E, Fluck, Nick, Shalev, Varda, Chodick, Gabriel, Blankestijn, Peter J, Van Zuilen, Arjan, Van den Brand, Jan A, Sarnak, Mark J, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen G, Nadukuru, Rajiv, Metzger, Marie, Flamant, Martin, Houillier, Pascal, Haymann, Jean-Philippe, Froissart, Marc, Kenealy, Timothy, Elley, Raina C, Collins, John F, Drury, Paul L, Cuddeback, John K, Ciemins, Elizabeth L, Stempniewicz, Rich, Nelson, Robert G, Knowler, William C, Bakker, Stephen J, Major, Rupert W, Medcalf, James F, Shepherd, David, Barrett-Connor, Elizabeth, Bergstrom, Jaclyn, Ix, Joachim H, Molnar, Miklos Z, Sumida, Keiichi, de Zeeuw, Dick, Brenner, Barry, Qureshi, Abdul R, Elinder, Carl-Gustaf, Runesson, Bjorn, Evans, Marie, Segelmark, Marten, Stendahl, Maria, Schön, Staffan, Naimark, David M, Tangri, Navdeep, Sud, Maneesh, Hirayama, Atsushi, Ichikawa, Kazunobu, Bilo, Henk JG, Landman, Gijs WD, Van Hateren, Kornelis JJ, Kleefstra, Nanne, Hallan, Stein I, Ballew, Shoshana H, Chen, Jingsha, Kwak, Lucia, Surapaneni, Aditya, Parving, Hans-Henrik, Rodby, Roger A., Rohde, Richard D, Lewis, Julia B, Lewis, Edmund, Perrone, Ronald D, Abebe, Kaleab Z, Hou, Fan F, Xie, Di, Hunsicker, Lawrence G, Imai, Enyu, Kobayashi, Fumiaki, Makino, Hirofumi, Ito, Sadayoshi, Remuzzi, Giuseppe, Ruggenenti, Piero, Eckardt, Kai-Uwe, Gudmundsdottir, Hrefna, Maciulaitis, Romaldas, Manley, Tom, Smith, Kimberly, Stockbridge, Norman, Thompson, Aliza, Vetter, Thorsten, Willis, Kerry, Zhang, Luxia, Coresh, Josef, Heerspink, Hiddo J L, Sang, Yingying, Matsushita, Kunihiro, Arnlov, Johan, Astor, Brad C, Black, Corri, Brunskill, Nigel J, Carrero, Juan-Jesus, Feldman, Harold I, Fox, Caroline S, Inker, Lesley A, Ishani, Areef, Jassal, Simerjot, Konta, Tsuneo, Polkinghorne, Kevan, Romundstad, Solfrid, Solbu, Marit D, Stempniewicz, Nikita, Stengel, Benedicte, Tonelli, Marcello, Umesawa, Mitsumasa, Waikar, Sushrut S, Wen, Chi-Pang, Wetzels, Jack F M, Woodward, Mark, Grams, Morgan E, Kovesdy, Csaba P, Levey, Andrew S, and Gansevoort, Ron T

Published
2019
Full Text
View/download PDF

50. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Author

Sevillano, Angel, Kamper, Anne-Lise, van Zuilen, Arjan D., Brenner, Barry M., Maes, Bart, Ihle, Benno U., Barret, Brendan, Leung, CB, Szeto, CC, Fitzner, Christina, Wanner, Christoph, Pozzi, Claudio, Montagnino, Claudio Ponticelli, Xie, Di, de Zeeuw, Dick, Lewis, Edmund, Verde, Eduardo, Gutierrez, Eduardo, Imai, Enyu, Hou, Fan Fan, Caravaca, Fernando, Fervenza, Fernando C., Locatelli, Francesco, Schena, Francesco Paolo, Kobayashi, Fumiaki, Moroni, Gabriella, Becker, Gavin J., Beck, Gerald J., Appel, Gerald B., Frisch, Gershon, van Essen, GG, Maschio, Giuseppe, Remuzzi, Giuseppe, Montogrino, Giuseppe, Parving, Hans-Henrik, Heerspink, Hiddo J.L., Makino, Hirofumi, Jehan, Imitiaz, Wetzels, Jack F.M., Donadio, James, Dwyer, Jamie, van den Brand, Jan, Kusek, John, Lachin, John M., Luño, Jose, Lewis, Julia B., Floege, Jürgen, Abebe, Kaleab Z., Chow, KM, Hunsicker, Lawrence G., del Vecchio, Lucia, Carlo, Manno, Praga, Manuel, Goicoechea, Marian, von Eynatten, Maximilian, Poulter, Neil, Chaturvedi, Nish, Passerini, Patrizia, de Jong, Paul E., Blankestijn, Peter J., Li, Philip, Ruggenenti, Piero, Zucchelli, Pietro, Kincaid-Smith, Priscilla S., Hilgers, Ralf-Dieter, Estacio, Raymond O., Rohde, Richard D., Katafuchi, Ritsuko, Toto, Robert D., Schrier, Robert W., Rodby, Roger A., Perrone, Ronald D., Ito, Sadayoshi, Klahr, Saulo, Andrulli, Simeone, Strandgaard, Svend, Chan, Tak Mao, Hannedouche, Thierry P., Rauen, Thomas, Greene, Tom, Verdalles, Ursula, Perkovic, Vlado, Keane, William, Heerspink, Hiddo J L, Tighiouart, Hocine, Gansevoort, Ron T, Coresh, Josef, Simon, Andrew L, Lewis, Julia B, Levey, Andrew S, and Inker, Lesley A

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results